Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by OISHI, N.
Right arrow Articles by TROUP, S. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by OISHI, N.
Right arrow Articles by TROUP, S. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 1960, Vol. 15, No. 6, pp. 863-872.
© 1960 American Society of Hematology, Inc.

Busulfan Therapy in Myeloid Metaplasia

NOBORU OISHI , SCOTT N. SWISHER , and STANLEY B. TROUP

1. Seven patients with myeloid metaplasia, massive splenomegaly and hypermetabolism were treated with busulfan in eight courses of therapy. In each instance, reduction in spleen size and improvement of symptoms occurred.

2. The total dose of busulfan in five of the cases ranged between 212 and 290 mg. Three of the patients developed leukopenia of moderate degree necessitating discontinuance of drug therapy.

3. It would appear that initial and maintenance doses of busulfan should be lower in patients with myeloid metaplasia than the doses customarily used in the treatment of patients with chronic myclocytic leukemia.

Submitted on August 5, 1959
Accepted on October 23, 1959


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Arch Intern MedHome page
A. T. WEBB, F. L. MEYER, and E. R. LONSER
Hemorrhagic Thrombocythemia: Response to Busulfan
Arch Intern Med, March 1, 1963; 111(3): 280 - 285.
[Abstract] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1960 by American Society of Hematology         Online ISSN: 1528-0020